<DOC>
	<DOCNO>NCT00546910</DOCNO>
	<brief_summary>This two-arm , parallel , randomize , double-blind , placebo-controlled Phase 4 multicenter trial compare whole day efficacy atomoxetine versus placebo child age 6 12 year Attention-Deficit/Hyperactivity Disorder ( ADHD ) treat inpatient , day-patient outpatient set Germany . Core symptom measure bi-weekly visit , three time per visit-day , computer base Continuous Performance Test . Following initial 3-28-day screening washout phase , patient assign double-blind treatment atomoxetine placebo . In verum arm , one-week atomoxetine treatment period 0.5 mg/kg per day lead-in dose succeed 7 week period target dose 1.2 mg/kg per day .</brief_summary>
	<brief_title>Comparison Atomoxetine Versus Placebo Children With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Male female patient least 6 year age , reach 13th birthday Diagnosis ADHD Normal intelligence Able swallow capsule Weight le 20 kg 60 kg study entry Prior treatment atomoxetine History seizure disorder , suicidal risk , alcohol drug abuse within past 3 month History severe allergy multiple adverse drug reaction Cardiovascular disorder : hypertension , unexplained cardiac sign symptom , QT prolongation , inherited cardiac disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>